LV10394B - Vaccines, method for preparation of them, method for preparation of immunogenic complex, method for preparation of matrix - Google Patents

Vaccines, method for preparation of them, method for preparation of immunogenic complex, method for preparation of matrix Download PDF

Info

Publication number
LV10394B
LV10394B LVP-93-753A LV930753A LV10394B LV 10394 B LV10394 B LV 10394B LV 930753 A LV930753 A LV 930753A LV 10394 B LV10394 B LV 10394B
Authority
LV
Latvia
Prior art keywords
quot
antigen
iskom
solubilizing agent
indicated
Prior art date
Application number
LVP-93-753A
Other languages
English (en)
Latvian (lv)
Other versions
LV10394A (lv
Inventor
Mackenzie Neill Moray
O'sullivan Angela Marie
Original Assignee
Mallinckrodt Veterinary Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Veterinary Ltd filed Critical Mallinckrodt Veterinary Ltd
Publication of LV10394A publication Critical patent/LV10394A/xx
Publication of LV10394B publication Critical patent/LV10394B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
LVP-93-753A 1989-09-01 1993-06-29 Vaccines, method for preparation of them, method for preparation of immunogenic complex, method for preparation of matrix LV10394B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898919819A GB8919819D0 (en) 1989-09-01 1989-09-01 Complexes having adjuvant activity
PCT/GB1990/001351 WO1991003256A1 (fr) 1989-09-01 1990-08-31 Complexes adjuvants

Publications (2)

Publication Number Publication Date
LV10394A LV10394A (lv) 1995-02-20
LV10394B true LV10394B (en) 1995-10-20

Family

ID=10662403

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-753A LV10394B (en) 1989-09-01 1993-06-29 Vaccines, method for preparation of them, method for preparation of immunogenic complex, method for preparation of matrix

Country Status (15)

Country Link
EP (2) EP0415794A1 (fr)
JP (1) JPH05500056A (fr)
AU (1) AU637405B2 (fr)
CA (1) CA2064911A1 (fr)
DD (1) DD297331A5 (fr)
GB (1) GB8919819D0 (fr)
HU (1) HU214110B (fr)
IE (1) IE903161A1 (fr)
LV (1) LV10394B (fr)
NZ (1) NZ235119A (fr)
PL (2) PL168055B1 (fr)
PT (1) PT95164B (fr)
WO (1) WO1991003256A1 (fr)
YU (1) YU166790A (fr)
ZA (1) ZA906977B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
CA2096650A1 (fr) * 1991-09-18 1993-03-21 Keith E. Langley Formulation de vaccin anti-hepatite a comprenant un sel d'acide biliaire
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
USRE39494E1 (en) * 1992-02-27 2007-02-27 Intervet Inc. Inactivated mycoplasma hyopneumoniae and uses therefor
EP0604727A1 (fr) * 1992-12-31 1994-07-06 American Cyanamid Company Immunogénéité améliorée d'un vaccin par incorporation d'un cytocine dans un complexe immunostimulant contenant un antigène
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
AUPP807399A0 (en) * 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
GB0008879D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) * 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
RS57350B1 (sr) 2011-10-03 2018-08-31 Mx Adjuvac Ab Nanočestice, postupak dobijanja i njihova primena kao nosača amfipatičnih ili hidrofobnih molekula u medicini, uključujući i terapiju kancera, kao i prehrambenih jedinjenja
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
CN114404583A (zh) * 2022-01-25 2022-04-29 龙岩学院 一种副猪嗜杆菌佐剂疫苗的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2039229T3 (es) * 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
AU2297888A (en) * 1988-09-30 1990-04-05 Lovgren, Karin A complex comprising adjuvants and lipids
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes

Also Published As

Publication number Publication date
EP0766967A1 (fr) 1997-04-09
HU9200666D0 (en) 1992-05-28
HUT61205A (en) 1992-12-28
AU637405B2 (en) 1993-05-27
PL168055B1 (pl) 1995-12-30
DD297331A5 (de) 1992-01-09
IE903161A1 (en) 1991-03-13
AU6335590A (en) 1991-04-08
EP0415794A1 (fr) 1991-03-06
NZ235119A (en) 1991-12-23
PL286711A1 (en) 1991-07-15
PL168316B1 (pl) 1996-02-29
CA2064911A1 (fr) 1991-03-02
YU166790A (sh) 1994-12-28
PT95164B (pt) 1997-09-30
JPH05500056A (ja) 1993-01-14
LV10394A (lv) 1995-02-20
GB8919819D0 (en) 1989-10-18
WO1991003256A1 (fr) 1991-03-21
PT95164A (pt) 1991-05-22
ZA906977B (en) 1992-05-27
HU214110B (en) 1997-12-29

Similar Documents

Publication Publication Date Title
LV10394B (en) Vaccines, method for preparation of them, method for preparation of immunogenic complex, method for preparation of matrix
Mayr et al. Bacterial ghosts as antigen delivery vehicles
Krivan et al. Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide (asialo GM1) and gangliotriaosylceramide (asialo GM2)
Giguère Macrolides, azalides, and ketolides
Kennedy et al. Effects of Escherichia coli heat-stable enterotoxin STb on intestines of mice, rats, rabbits, and piglets
Arab et al. Influence of phospholipid chain length on verotoxin/globotriaosyl ceramide binding in model membranes: comparison of a supported bilayer film and liposomes
van Putten et al. Molecular mechanisms of Campylobacter infection
Strange et al. The fbpABC operon is required for Ton-independent utilization of xenosiderophores by Neisseria gonorrhoeae strain FA19
US6410012B1 (en) Antimicrobial mediated bacterial DNA delivery
CN101896197A (zh) 来自艰难梭菌的新型多糖免疫原
US5178860A (en) Adjuvant complexes and vaccine made therefrom
EP2384190B1 (fr) Formulations de cellules viables pour une administration orale
Mullineaux-Sanders et al. Citrobacter amalonaticus Inhibits the Growth of Citrobacter rodentium in the Gut Lumen
Sannasiddappa et al. Staphylococcus aureus MnhF mediates cholate efflux and facilitates survival under human colonic conditions
LEVITZ et al. Sulfurylation of estrogens by the human fetus
WO2014198857A1 (fr) Hydrolase de sels biliaires bsh1 pour réguler la prise de poids et les niveaux de cholestérol sérique et de triglycérides hépatiques chez un mammifère et souches bactériennes exprimant des variants de bsh1
Fuller et al. Legionnaires' disease after heart transplantation
Low-Beer et al. Diarrhoea: mechanisms and treatment.
Crowlesmith et al. Bacteriophage P22 is not a likely probe for zones of adhesion between the inner and outer membranes of Salmonella typhimurium
Johnson et al. Uptake and subcellular localization of tritiated spermine in Escherichia coli
Hiroshi et al. Inhibition of drug-metabolizing enzymes in the mouse after treatment with host-mediating antitumor drugs
Edwards et al. Protection of live bacteria from bile acid toxicity using bile acid adsorbing resins
Richardson et al. A novel cold-chain free VCG-based subunit vaccine protects against Chlamydia abortus-induced neonatal mortality in a pregnant mouse model
US20190117684A1 (en) Meningococcal vaccine based on lipooligosaccharide (LOS) originating from modified Neisseria meningitidis strains of immunotype L6
RæRregaard et al. The influence of properties encoded by the Yersinia virulence plasmid on adhesion of Yersinia enterocolitica to ileal brush border membrane vesicles